4-(4-methylphenyl)-1-(methylsulfonyl)piperidine | 895572-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-methylphenyl)-1-(methylsulfonyl)piperidine
• 英文别名: 4-(4-Methylphenyl)-1-methylsulfonylpiperidine
• CAS: 895572-73-3
• 化学式: C₁₃H₁₉NO₂S
• 分子量: 253.365
• InChiKey: BZBCSOJFHRSKPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020210383A1

  公开（公告）日：2020-10-15

  Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了一种作为Weel抑制剂的杂环化合物。这些化合物可能用作治疗疾病的治疗剂，特别是在肿瘤学中可能具有特殊用途。
• SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20150284387A1

  公开（公告）日：2015-10-08

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having pyrazolopyridine structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有吡唑吡啶结构的新型小分子，其作为Mcl-1蛋白抑制剂的功能，以及它们作为治疗癌症和其他疾病的药物的用途。
• Sulfonyl Amino Cyclic Derivatives and Use Thereof
  申请人：Swinnen Dominique

  公开号：US20080194520A1

  公开（公告）日：2008-08-14

  The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

  本发明涉及公式（I）的衍生物及其在特定疾病的治疗和/或预防中的应用，特别是在自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、癌症、呼吸系统疾病和纤维化等方面的应用，包括多发性硬化症、关节炎、肺气肿、慢性阻塞性肺疾病、肝纤维化和肺纤维化。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150353495A1

  公开（公告）日：2015-12-10

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及式I化合物及其药学上可接受的盐、酯和前药，它们是JAK激酶抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由JAK激酶活性介导的多种疾病，如不良血栓形成和非霍奇金淋巴瘤的方法。
• SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS
  申请人：LABORATOIRES SERONO S.A.

  公开号：EP1828160A1

  公开（公告）日：2007-09-05